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Abstract
Background: Cannabinoids bind to cannabinoid receptors CB1 and CB2 and have been reported to possess anti-tumorigenic
activity in various cancers. However, the mechanisms through which cannabinoids modulate tumor growth are not well
known. In this study, we report that a synthetic non-psychoactive cannabinoid that specifically binds to cannabinoid
receptor CB2 may modulate breast tumor growth and metastasis by inhibiting signaling of the chemokine receptor CXCR4
and its ligand CXCL12. This signaling pathway has been shown to play an important role in regulating breast cancer
progression and metastasis.
Methodology/Principal Findings: We observed high expression of both CB2 and CXCR4 receptors in breast cancer patient
tissues by immunohistochemical analysis. We further found that CB2-specific agonist JWH-015 inhibits the CXCL12-induced
chemotaxis and wound healing of MCF7 overexpressing CXCR4 (MCF7/CXCR4), highly metastatic clone of MDA-MB-231
(SCP2) and NT 2.5 cells (derived from MMTV-neu) by using chemotactic and wound healing assays. Elucidation of the
molecular mechanisms using various biochemical techniques and confocal microscopy revealed that JWH-015 treatment
inhibited CXCL12-induced P44/P42 ERK activation, cytoskeletal focal adhesion and stress fiber formation, which play a
critical role in breast cancer invasion and metastasis. In addition, we have shown that JWH-015 significantly inhibits
orthotopic tumor growth in syngenic mice in vivo using NT 2.5 cells. Furthermore, our studies have revealed that JWH-015
significantly inhibits phosphorylation of CXCR4 and its downstream signaling in vivo in orthotopic and spontaneous breast
cancer MMTV-PyMT mouse model systems.
Conclusions/Significance: This study provides novel insights into the crosstalk between CB2 and CXCR4/CXCL12-signaling
pathways in the modulation of breast tumor growth and metastasis. Furthermore, these studies indicate that CB2 receptors
could be used for developing innovative therapeutic strategies against breast cancer.
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Introduction
Cannabinoids exert their effects by binding with two heptahelical
Gai/Gao-protein-coupled receptors, CB1 and CB2.C B 1 receptors
are expressed predominantly in the central nervous system, whereas
CB2 receptor is mainly expressed by the cells of the immune system
[1,2]. Many selective agonists which have significantly higher
affinities for their specific receptors have been developed. CB1-
specific agonists include synthetic cannabinoids methanandamide
(Met-f-AEA), arachidonylcyclopropylamide (ACPA), and arachido-
nyl-2-chloroethylamide (ACEA), whereas synthetic cannabinoids
JWH-015 and JWH-133 specifically bind to cannabinoid receptor
CB2. Cannabinoids have been shown to inhibit proliferation and
growth of various cancers including breast, liver, prostate, skin, and
lung in in vitro and in vivo mouse models [3,4,5,6,7]. Cannabinoids
have also been shown to directly induce apoptosis by causing cell
cycle arrest in neoplastic cells [8,9]. Furthermore, experimental
evidence has shown that cannabinoidsmay also inhibit angiogenesis
in vitro and in vivo [3,5,7,10,11,12,13]. Although cannabinoid
receptors have been shown to modulate several signaling pathways
involved in the control of cell survival, not much is known about
their role in the regulation of chemokine receptor CXCR4-
mediated signaling in tumors [5,6,14].
Chemokine receptor CXCR4 is a seven membrane spanning G-
protein coupled receptor and has been shown to be overexpressed
on various malignant cancers including breast cancer [15,16].
CXCR4 binds to its cognate ligand CXCL12, also known as
stromal-derived factor 1-a (SDF1a). The CXCR4/CXCL12
receptor axis has been shown to play an important role in
metastasis of CXCR4-expressing tumor cells to organs and tissues
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lymph nodes, lungs, and brain [17,18,19]. Overexpression of
CXCR4 is associated with metastasis and poor prognosis of breast
cancer [20,21,22,23,24,25]. CXCR4/CXCL12 axis has been
shown to enhance tumor growth by modulating tumor stroma
through activation of cancer-associated fibroblasts and recruitment
of CXCR4-positive endothelial precursor cells, thereby enhancing
angiogenesis [26]. Targeting CXCR4 with neutralizing antibodies
and small molecule antagonists has been shown to inhibit breast
tumor growth and metastasis in vitro and in vivo [19,27,28,29,30].
CXCL12/CXCR4 signaling axis has also been shown to
modulate focal adhesion complexes which regulate cell migration
[31]. Focal adhesions are the primary links between the cell and
the extracellular matrix (ECM), formed by focal adhesion kinase
(FAK) and vinculin, which connect integrins to the actin
cytoskeleton [32]. Appropriate regulation of fiber association and
disassociation, mediated by FAK and vinculin, is important for
controlling cellular migration and signaling [32]. Actin stress fibers
are anchored in focal adhesions and are responsible for cell
traction and ECM reorganization [33].
In the present study, we have analyzed the effects of synthetic
non-psychoactive cannabinoid JWH-015 that specifically binds to
CB2 receptors on breast cancer and have shown that this
compound inhibits CXCL12/CXCR4-induced breast cancer
invasive properties in vitro. In addition, we have shown that it
inhibits growth in in vivo mouse model systems. Furthermore, our
signaling studies in breast cancer cell lines as well as in tumors
derived from experimental mice have revealed that synthetic
cannabinoids inhibit tumorigenesis by suppressing the phosphor-
ylation of CXCR4 and its downstream target, ERK. This study
provides novel insights about anti-tumorigenic effects of CB2
receptors in breast cancer through modulation of CXCR4/
CXCL12 signaling axis. Furthermore, these studies suggest that
CB2 could be developed as a potential therapeutic target against
breast cancer growth and metastasis.
Materials and Methods
Reagents and antibodies
Cell culture reagents were purchased from Gibco Laboratories
(Grand Island, NY). The following reagents and antibodies used in
this study were purchased from different sources: anti-CB2
(Affinity Bioreagents, Golden, CO, USA); JWH-015 (Tocris
Cookson, Ellisville, MO); human CXCL12 and murine CXCL12
(Peprotech); vinculin (Sigma); pCXCR4/CXCR4 (Abcam);
pERK/ERK (Santa Cruz); Phalloidin-568 (Invitrogen); and
Ki67 (NeoMarkers).
Cell culture
MCF-7/CXCR4 (kindly provided by Dr. Ann Richmond,
Vanderbilt University School of Medicine, Nashville, TN) [34]
and SCP2, a subclone of MDA-MB-231 cells (kindly provided by
Dr. Joan Massague ´, Memorial Sloan-Kettering Cancer Center,
New York, NY) [35], and NT2.5 cells (obtained from Dr. Gustavo
Leone laboratory, The Ohio State University) [36] were cultured
in DMEM containing 10% heat-inactivated fetal bovine serum
(FBS), 5 units/mL penicillin, and 5 mg/mL streptomycin.
Western blot analysis
Cells plated in 100 cm
2 dishes were lysed in lysis buffer (50 mM
Tris–HCl, 150 mM NaCl, 0.5% Triton X-100, 0.5% deossicolic
acid, 10 mg/ml leupeptin, 2 mM phenylmethylsulfonyl fluoride,
10 mg/ml aprotinin) and tumor samples were homogenized in cell
lysis buffer (Cell Signaling Technologies, Beverly, MA, USA).
50 mg of proteins was loaded on 4–12% SDS–polyacrylamide gels
(Invitrogen) under reducing conditions, transferred to nitrocellu-
lose membranes (BioRad) and blocked with 5% milk. Membranes
were incubated overnight with primary antibody, washed three
times, and incubated for 1 h at RT with horseradish peroxidase-
conjugated secondary antibody. The membranes then were
washed and stained using a chemiluminescence system (ECL-
Amersham Biosciences) and exposed to X-ray film (Kodak).
Confocal Microscopy
Confocal microscopy was carried out as described previously
[4,5]. Briefly, cells were plated on 2-mm glass coverslips coated
with 15 mg/ml of poly-L-lysine and cultured in complete DMEM
for 24 h. After treatment with JWH-015 and stimulation with
CXCL12, cells were fixed with 4% paraformaldehyde, blocked
with 5% normal goat serum for 60 min, incubated in FITC-
labeled anti-vinculin (Sigma) or Phalloidin-568 for 2 h at RT.
Images were acquired using Leica Axiovert S100 TV microscope
(Carl Zeiss, Oberkochen, Germany).
Chemotactic Assays
Chemotactic assays were performed using transwell chambers
(Costar 8.0 mm pore size) as described previously [4,5]. Briefly,
serum starved MCF-7/CXCR4, SCP2 and NT2.5 cells were
pretreated with JWH-015 or vehicle (20 mM) overnight. Top
chambers were loaded with 150 mLo f1 610
6 cells/ml in serum-
free medium and bottom chambers contained serum-free medium
in the presence or absence of CXCL12 (100 ng/ml). Cells that
migrated across the membrane after 6 h were counted by fixing in
37% formaldehyde and 25% glutaraldehyde in PBS and staining
with 0.1% crystal violet in PBS for 30 minutes. The number of
migratory cells per membrane was measured by light microscopy,
counted in 5 fields and the percentage of migration determined.
Wound healing Assay
Wound healing assays were performed as described previously
[4]. Briefly, cells were grown to 70% confluence in complete
DMEM. Monolayers were wounded by scratching with a sterile
plastic 200 mL micropipette tip, washed, and incubated in DMEM
with 0.1% FBS in the presence or absence of JWH-015 or vehicle
and CXCL12 (100 ng/ml). After 18 or 24 h, cells were fixed with
4% paraformaldehyde in PBS for 5 min at RT and photographed
using a low-magnification phase-contrast microscope. The extent
of migration into the wound area was evaluated qualitatively using
ImageJ software.
Flow cytometry assay
Cells were grown in 6-well plates for 24 h, incubated in 2 mM
EDTA, removed from plates, and fixed with ice cold 70% ethanol
in PBS. After centrifugation, pellets were resuspended and stained
with primary antibodies for 30 min. Samples were analyzed by
flow cytometry (BD FACS Calibur) at RT in the dark.
Animal Studies
In vivo experiments were done in compliance with the
guidelines and protocols approved by Institutional Animal
Care and Use Committee of The Ohio State University
(2007A0233-R1). FVB mice (Charles River Laboratories Inc.)
were used for orthotopic tumor studies at 4 to 6 wk of age.
Tumors were induced by injecting NT 2.5 cells 3610
6 (100 mL)
into the #4 mammary gland of FVB mice. When tumors were
palpable, the animals were assigned randomly to various groups
(n=5) and injected peritumorally with JWH-015 (5 mg/kg) or
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every wk with external calipers and tumor volume was
calculated according to the formula V=0.52 6a
26b,w h e r ea
is the smallest superficial diameter and b is the largest
superficial diameter [5,37].
Female heterozygous PyMT mice (n=5) were treated either
with JWH-015 (5 mg/kg body weight) or vehicle, daily for 28
days. After 8 wk, mice were sacrificed and tumors were dissected,
weighed, and divided into pieces, which were snap frozen in liquid
nitrogen for protein analysis [5].
Figure 1. Expression of CXCR4 and CB2 receptors in primary breast cancer tissues and cell lines. (A) Representative photomicrographs of
immunohistochemical staining of primary breast cancer tissues showing CXCR4 and CB2 staining. Scale bars 50 mm and 200 mm. (B). FACS analysis of
cell surface expression of CXCR4 and CB2 in MCF-7/CXCR4, SCP2 and MMTV-neu (NT 2.5) cells.
doi:10.1371/journal.pone.0023901.g001
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Tissue microarrays from paraffin-embedded formalin fixed
breast cancer tissue specimens were prepared as described earlier
[5]. These tissue microarrays were obtained from the Human
Tissue Resource Network, Department of Pathology, The Ohio
State University. Samples were stained with CXCR4 antibody
(Abcam) in a 1:100 dilution and CB2 antibody (Affinity Bio-
Reagent) in a 1:200 dilution and detected using a kit (Vector
Laboratories) as described earlier [5]. Slides were visualized with
3,39-diaminobenzidine chromogen for the intensity and analysis of
CXCR4 and CB2 expression.
Samples from tumor xenografts of mice were dissected,
embedded in OCT (Tissue-Tek) and stained using standard
immunohistochemistry techniques as per the manufacturer’s
recommendation (Vector Laboratories), using the primary anti-
body against Ki-67 (Neomarkers) at a dilution of 1:100. Slides
were stained with secondary antibodies and detected as described
earlier [4,5].
Statistical analysis
Student’s two-tailed t test was used to compare vehicle and
cannabinoid-treated groups. p,0.05 was considered to be
statistically significant. For all graphs,
*indicates P,0.05;
**indi-
cates P,0.01.
Results
Primary breast cancer tissues express CB2 and CXCR4
Cannabinoids have been shown to exert their effects through
cannabinoid receptors CB1 and CB2. However, not much is
known about the role of CB2 receptors in modulating CXCR4-
mediated effects in breast cancer. To elucidate the role of CB2 and
CXCR4 in breast cancer, we assessed their expression in tumor
samples from 82 breast cancer patients using tissue microarrays.
We observed expression of CB2 (58%) and CXCR4 (90%) in these
cases (Fig. 1A). In addition, MCF-7/CXCR4 (MCF-7 overex-
pressing CXCR4), SCP2 (highly metastatic MDA-MB-231 clone),
and NT 2.5 cells (derived from MMTV-neu mice) were shown to
express both CXCR4 and CB2 (Fig. 1B) by Flow cytometry.
CB2 agonist JWH-015 inhibits CXCL12-induced migration
and invasion of breast cancer cells
CXCR4/CXCL12 signaling axis has been shown to promote
migration and invasion of breast cancer cells to distant sites of
metastasis such as the lung, brain, bone, lymph nodes, and liver
[19,31,38]. Hence, to evaluate the potential of CB2 as a possible
therapeutic target, the effect of CB2 agonist JWH-015 on
CXCL12-induced cell migration was investigated. As shown in
Fig. 2, JWH-015 (20 mM) showed significant inhibition of
CXCL12-induced migration of MCF-7/CXCR4 and SCP2 cells.
We further analyzed the effect of JWH-015 on CXCL12-induced
invasion using wound healing assays. We observed a significant
inhibition of CXCL12-induced wound healing in MCF-7/
CXCR4, SCP2, and NT 2.5 after overnight pretreatment with
JWH-015 (20 mM) compared to the vehicle-treated cells (Fig. 3).
Thus these results suggest that CB2 receptor specific agonists
significantly reduced CXCL12/CXCR4-induced migration and
invasion of breast cancer cells.
CB2 agonist JWH-015 inhibits CXCR4/CXCL12-mediated
signaling in breast cancer cells
CXCR4/CXCL12 has been shown to induce growth and
migration of different types of cells by activating various signaling
pathways including activation of p44/p42 ERK [15,34,39]. We
analyzed the effect of JWH-015 on CXCL12-induced signaling
and observed that it inhibits phosphorylation of p44/p52 MAPK
in SCP2 cells (Fig. 4).
CXCL12 has also been shown to modulate focal adhesion
complexes which regulate cell migration [31]. We analyzed the
effect of JWH-015 on CXCL12-induced focal adhesion formation
and actin stress fiber formation in various breast cancer cell lines.
As shown in Fig. 5A, JWH-015 inhibited focal adhesion
formation as detected by changes in vinculin on the cellular
membrane using immunofluorescence in MCF-7/CXCR4 cells.
In addition, we observed that JWH-015 inhibited CXCL12-
mediated actin stress fiber formation in SCP2 cells (Fig. 5B).
These studies indicate that CB2-specific agonists may modulate
cell migration by inhibiting actin stress fiber and focal adhesion
formation.
Figure 2. CB2 agonist inhibits CXCL12-induced cell migration in breast cancer cells. Breast cancer cells (A) MCF-7/CXCR4-WT and (B) MDA-
MB231 (SCP2) were pretreated overnight with vehicle or JWH-015 (20 mM) and 1610
5 cells were plated on the top chamber of 8 mm pore
polycarbonate membrane filters and medium in absence or presence of CXCL12 (100 ng/ml) was placed in the lower chamber. After 12 hours of
incubation, cells that migrated across the filter towards medium with or without CXCL12 (100 ng/ml) were fixed, stained and counted by bright-field
microscopy in five random fields. Data represent the mean 6 SD, representative experiments (n=3) are shown. *P,0.05 vs. vehicle. Veh: Vehicle.
doi:10.1371/journal.pone.0023901.g002
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mouse models by downregulation of CXCR4-mediated
signaling
To further analyze the effect of CB2 agonists on in vivo growth and
proliferation, we induced tumors by injecting NT 2.5 cells into
syngenic (FVB) mice and treated them with JWH-015 or vehicle for
4 wk. NT 2.5 cells have been derived from MMTV-neu mouse models
(FVB) and have been used for analyzing breast tumor growth in
syngenic mouse models [36]. We observed a significant inhibition of
tumor formation in JWH-015 treated mice compared to the vehicle
treated group (Fig. 6A to C). In addition, there was a significant
decrease in proliferation as indicated by downregulation of Ki67
(proliferation marker) immunostaining in JWH-015-treated compared
to the vehicle-treated tumors (Fig. 6D) [40]. To further elucidate the
mechanism of inhibition, we analyzed the tumors extracted from
JWH-015 or vehicle treated mice. We observed a significant decrease
in the phosphorylation of CXCR4 and ERK in tumors treated with
JWH-015 compared to vehicle treated tumors (Fig. 6E). However, no
change in total protein levels of ERK and CXCR4 were observed in
JWH-015 compared to vehicle-treated tumors.
Figure 3. CB2 agonist inhibits CXCL12-induced wound healing in breast cancer cells. Breast cancer cells (A) MCF-7/CXCR4-WT, (B) MDA-
MB231 (SCP2), and (C) MMTV-neu (NT 2.5, murine mammary cells) were grown for confluence in complete medium in six-well plates and then
scratched with a 200 ml pipette tip to make wounds. The cells were treated with vehicle or JWH-015 (20 mm) and the closure of the wounds was
monitored in presence or absence of CXCL12 (100 ng/ml) by microscopy after 18 or 24 hrs. Quantitative analysis of % wound closure as shown in left
panels was determined my ImageJ software. Data represent the mean 6 SD, representative experiments (n=3) are shown. *P,0.05 vs. vehicle;
**P,0.005 vs. vehicle. Veh: Vehicle.
doi:10.1371/journal.pone.0023901.g003
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aggressive spontaneous mammary tumor formation in transgenic
PyMT mice after treatment with JWH-015 compared to the
vehicle-treated group [5]. To further confirm the effect of JWH-
015 on phosphorylation of ERK and CXCR4 in vivo, we analyzed
the cell lysates of tumors derived from JWH-015 or vehicle-treated
PyMT mice. We observed a significant decrease in the
phosphorylation of CXCR4 and ERK in tumors extracted from
JWH-015 treated mice compared to the vehicle treated group
(Fig. 6F). Taken together, these results suggest that JWH-015
inhibits tumor growth in vivo. Furthermore, these studies indicate
that the inhibition of tumorigenesis may be caused by a decrease of
CXCR4 phosphorylation that may lead to lower ERK phosphor-
ylation and thereby reduce proliferation.
Discussion
Breast cancer is the second leading cause of cancer death in
women in the United States. Despite recent advances in hormonal
therapies, mortality still remains high due to breast cancer
metastasis to other organs. Synthetic cannabinoids that bind to
cannabinoid receptors CB1 and CB2 have been shown to inhibit
migration, metastasis, and invasion of various cell types including
breast cancer cells [4,5,6,37,41]. However, not much is known
about the mechanisms by which CB1 and CB2 mediate their
inhibitory effects. The majority of breast cancers have been shown
to overexpress chemokine receptor CXCR4, which has been
correlated with poor prognosis [34]. Furthermore, high CXCR4
expression was also correlated to poor clinical outcome in triple
negative breast cancers, which are difficult to treat [39,42]. Here,
we report for the first time that CB2 specific synthetic agonist
inhibits CXCL12-induced migration and invasion of breast cancer
cell lines in vitro. Furthermore, we have shown that this compound
inhibits tumor growth in vivo and downmodulates CXCR4
phosphorylation and downstream signaling.
We observed expression of CXCR4 (90%) and CB2 (58%) in
primary human tumor breast cancer samples by tissue microarray
analysis. We also found that both CXCR4 and CB2 receptors are
expressed on various breast cancer cell lines, including the highly
invasive triple negative breast cancer cell line SCP2. Although
CXCR4 and CB2 have previously been shown to be expressed by
breast cancer tissues, this is the first report showing co-expression
of these receptors on breast cancer tissues and cells.
CXCR4 and its cognate ligand CXCL12 have been shown to
play an important role in regulating metastasis of breast cancer to
specific organs [19,39,43]. Our results show that CB2 agonist
JWH-015 significantly inhibits CXCL12-induced cell migration
and wound healing in breast cancer cells. Previously, CB2 agonists
have been shown to modulate CXCL12-induced migration of T-
cells [44]. Wound healing and cell migration have been shown to
play an important role in regulating breast cancer cell metastasis.
These results suggest that CB2 receptor activation may modulate
breast cancer metastasis by inhibiting the CXCR4/CXCL12
signaling axis.
The molecular mechanisms involved in CB2-mediated inhibi-
tion of migration/invasion induced by CXCR4/CXCL12 are not
well characterized. We have shown that JWH-015 inhibits
CXCL12-induced phosphorylation of p44/p42 ERK in breast
cancer cells. CXCL12 has been shown to induce various signaling
pathways including p44/p42 ERK in breast cancer and other cell
types [15,34,39,45,46,47,48,49]. Previously, ERK has been shown
to regulate migration of several cell types [47,50]. We also
observed that JWH-015 inhibits CXCL12-induced focal adhesion
Figure 5. CB2 agonist inhibits CXCL12-induced focal adhesions and stress fibres formation. Confocal microscopic visualization of (A)
MCF-7/CXCR4 for focal adhesion (stained for Vinculin) or (B) SCP2 cells for stress fibers (stained for phalloidin). The cells were pretreated with vehicle
or JWH-015 (20 mm) overnight and then stimulated with CXCL12 (100 ng/ml; 30 min).
doi:10.1371/journal.pone.0023901.g005
Figure 4. CB2 agonist inhibits CXCL12-induced ERK phosphor-
ylation. MDA-MB231 (SCP2) cells were treated overnight with vehicle
or JWH-015 (20 mm) and stimulated with CXCL12 (100 ng/ml) for
different time periods. Cell lysates were analyzed for Phospho-ERK (p-
ERK), ERK and GAPDH by Immunoblotting.
doi:10.1371/journal.pone.0023901.g004
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cancer cells. Focal adhesions and actin stress fibers have been
shown to play an important role in cell migration and metastasis
[51,52]. Focal adhesions contain transmembrane integrin recep-
tors that join the ECM to actin stress fibers [32,33,51]. Actin stress
fibers are anchored in focal adhesions and are responsible for cell
traction and ECM reorganization [33]. The actin cytoskeleton
plays an important role in defining cell shape, morphology, and
regulating cellular migration. FAK and vinculin are responsible for
focal adhesion turnover and can be monitored for altered cellular
behavior [32,51]. Inhibition of FAK and vinculin causes a
significant decrease in normal cell spreading and migration of
breast cancer cells [32]. Increased actin stress fiber polymerization
has been correlated with enhanced cell wound healing and
motility [53]. Our results suggest that JWH-015-mediated effects
of p44/p42 ERK, focal adhesion formation, and actin stress fiber
polymerization may lead to reduced CXCL12-induced motility
and wound healing capability of breast cancer cells.
Mouse models are valuable tools for exploring and understand-
ing molecular mechanisms of breast cancer progression and
metastasis. In this study we used syngenic MMTV-neu mouse
models to analyze the effect of JWH-015 on breast cancer tumor
growth in vivo. We observed a significant reduction in orthotopic
tumor growth in mice treated with JWH-015 compared to vehicle
controls. These studies are consistent with previous studies using
PyMT and MMTV-neu transgenic mouse models for breast
cancer [5,41]. We showed that JWH-015 significantly inhibits
breast cancer growth and proliferation in mice injected with NT
2.5 cells. Further, analyses of tumors derived from syngenic and
PyMT transgenic mouse models indicated that JWH-015 inhibited
phosphorylation of CXCR4 and ERK without decreasing total
protein expression. This is the first report indicating that CB2
agonist JWH-015 inhibits CXCR4 phosphorylation in vivo. These
studies suggest that CB2 may crosstalk with CXCR4 receptors to
downregulate their signaling mechanisms.
The results of this study suggest that CB2-specific non-
psychoactive synthetic cannabinoid JWH-015 inhibits CXCL12-
induced migration and invasive properties of breast cancer cells.
Furthermore, elucidation of signaling mechanisms reveals that
JWH-015 inhibits CXCL12-induced CXCR4 and ERK phos-
phorylation, focal adhesion formation and actin stress fiber
polymerization. Thus, we conclude that CB2-specific synthetic
Figure 6. CB2 agonist inhibits tumor growth in syngenic mouse models. NT 2.5 cells (2610
6 in 100 ul PBS) were implanted orthotopically
into mammary gland (#4) of mice. Experimental mice (n=5) were treated peritumorally either with JWH-015 (5 mg/kg body wt) or vehicle on
alternate days for 28 days starting 14 days after injection of the cells. (A) Tumors were measured every wk with external calipers and tumor volume
was calculated according to the formula V=0.526a
26b, where a is the smallest superficial diameter and b is the largest superficial diameter. (B) After
28 days, the tumors were excised and weighed. (C) A representative photograph of mice showing tumors dissected from vehicle or JWH-015 treated
groups. (D) Representative photomicrographs of immunostaining with Ki67 (proliferation marker) of tumors extracted from JWH-015 treated mice
compared to vehicle treated. Scale bars, 50 mm. (E) Tumor lysates from mice treated with JWH or vehicle were analyzed for Phospho-CXCR4 (pCXCR4),
CXCR4, Phospho-ERK (pERK), ERK and GAPDH by Immunoblotting. (F) Tumor lysates derived from PyMT transgenic mice treated with JWH or vehicle
and analyzed for pERK, ERK, pCXCR4 and CXCR4 by Immunoblotting. *P,0.05 vs. vehicle. Veh: Vehicle.
doi:10.1371/journal.pone.0023901.g006
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to design novel therapies against breast cancer growth and
metastasis by blocking CXCR4/CXCL12-induced signaling.
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